Ovid Therapeutics
OVID
75 hedge funds and large institutions have $54.7M invested in Ovid Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 8 closing their positions.
262% more call options, than puts
Call options by funds: $47K | Put options by funds: $13K
113% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 15
54% more capital invested
Capital invested by funds: $35.4M → $54.7M (+$19.3M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 74 → 75 (+1)
0.41% more ownership
Funds ownership: 64.87% → 65.28% (+0.41%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$355K |
| 2 |
BlackRock
New York
|
+$337K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$225K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$191K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$147K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.92M |
| 2 |
FWM
FFT Wealth Management
Philadelphia,
Pennsylvania
|
-$377K |
| 3 |
TA
TLS Advisors
Miami,
Florida
|
-$370K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$361K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$179K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
76
Artal Group
Luxembourg
| – | -$1.92M | -2,500,000 | Closed |
|
|
FWM
77
FFT Wealth Management
Philadelphia,
Pennsylvania
| – | -$377K | -489,552 | Closed |
|
78
Wellington Management Group
Boston,
Massachusetts
| – | -$89.1K | -115,832 | Closed |
|
79
Millennium Management
New York
| – | -$60K | -78,024 | Closed |
|
|
DMKJ
80
David M. Knott Jr
| – | -$15K | -20,000 | Closed |
|
|
BBA
81
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$8.32K | -13,282 | Closed |
|
82
Two Sigma Investments
New York
| – | -$9.71K | -12,628 | Closed |
|
83
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1.73K | -2,250 | Closed |
|
OVID Hedge Fund Activity: Q3 2024 in Review
75 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2024, worth a combined $54.7M — up 54% from $35.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OVID positions and 8 closed out — a net gain of 1 holder — while 32 added to existing stakes and 15 trimmed.
The largest buyer was UBS O'Connor, adding an estimated $355K. The largest seller was Artal Group, exiting entirely with an estimated $1.92M sold.
- 75 institutional investors held Ovid Therapeutics (OVID) as of Q3 2024, up from 74 in Q2 2024.
- Funds reported $54.7M of Ovid Therapeutics stock for Q3 2024, up 54% quarter-over-quarter.
- 9 funds opened new Ovid Therapeutics positions in Q3 2024 and 8 closed out, a net change of +1 holder.
- The largest Ovid Therapeutics buyer in Q3 2024 was UBS O'Connor, an estimated $355K added.
- The largest Ovid Therapeutics seller in Q3 2024 was Artal Group, an estimated $1.92M sold.
Based on aggregated 13F filings for Q3 2024.